The efficacy of the anthracycline prodrug daunorubicin-GA3 in human ovarian cancer xenografts

British Journal of Cancer

Volumn 78, Issue 12, 1998, Pages 1600-1606

  Houba, P H J ^a   Boven, E ^a   Erkelens, C A M ^a   Leenders, R G G ^b   Scheeren, J W ^b   Pinedo, H M ^a   Haisma, H J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

Anthracycline glucuronide prodrug; Daunorubicin; Human ovarian cancer xenografts; Human glucuronidase; Targeting; Tumour therapy

Indexed keywords

ANTHRACYCLINE; BETA GLUCURONIDASE; CARBAMIC ACID DERIVATIVE; DAUNORUBICIN DERIVATIVE; PRODRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG ACTIVATION; DRUG EFFICACY; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MAXIMUM PERMISSIBLE DOSE; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; TUMOR NECROSIS; TUMOR VOLUME; XENOGRAFT;

EID: 0031739137     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.729     Document Type: Article

References (20)

1. Albin N, Massaad L, Toussaint C, Mathieu M-C, Morizet J, Parise O, Gouyette A and Chabot GG (1993) Main drug-metabolizing enzyme systems in human breast tumors and peritumoral tissues. Cancer Res 53: 3541-3546
2. Bagshawe KD, Springer CJ, Searle F, Antoniw P, Sharma SK, Melton RG and Sherwood RF (1988) A cytotoxic agent can be generated selectively at cancer sites. Br J Cancer 58: 700-703
3. Bosslet K, Czech J and Hoffman D (1995) A novel one-step tumor-selective prodrug activation system. Tumor Targeting 1: 45-50
4. Boven E, Winograd B, Fodstad O, Lobbezoo MW and Pinedo HM (1988) Preclinical phase II studies in human tumor lines: a European multicenter study. Eur J Cancer Clin Oncol 24: 567-573
5. Boven E, Hendriks HR, Erkelens CAM and Pinedo HM (1992) The anti-tumour effects of the prodrugs N-L-leucyl-doxorubicin and vinblastine-isoleucinate in human ovarian cancer xenografts. Br J Cancer 66: 1044-1047
6. Boven E, De Jong J, Kuiper CM, Bast A and Van der Vijgh WJF (1996) Relationship between the tumour tissue pharmacokinetics and antiproliferative effects of anthracyclines and their metabolites. Eur J Cancer 32A: 1382-1387
7. Chakravarty PK, Carl PL, Weber MJ and Katzenellenbogen JA (1983) Plasmin-activated prodrugs for cancer chemotherapy. 2. Synthesis and biological activity of peptidyl derivatives of doxorubicin. J Med Chem 26: 638-644
8. Connors TA and Whisson ME (1966) Cure of mice bearing advanced plasma cell tumours with aniline mustard: the relationship between glucuronidase activity and tumour sensitivity. Nature 210: 866-867
9. De Jong J, Guerand WS, Schoofs WPR, Bast A and Van der Vijgh WJF (1991) Simple and sensitive quantification of anthracyclines in mouse atrial tissue using high-performance liquid chromatography and fluorescence detection. J Chromatogr 570: 209-216
10. Deprez-de Campeneere D, Baurain R and Trouet A (1982) Accumulation and metabolism of new anthracycline derivatives in the heart after i.v. injection into mice. Cancer Chem Pharmacol 8: 193-197
11. Fishman WH (1970) Metabolic Conjugation and Metabolic Hydrolysis. Academic Press: New York
12. Frei E and Canellos GP (1980) Dose: a critical factor in cancer chemotherapy. Am J Med 69: 585-590
13. Haisma HJ, Boven E, Van Muijen M, De Jong J, Van der Vijgh WJF and Pinedo HM (1992) A monoclonal antibody-β-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer. Br J Cancer 66: 474-478
14. Hamilton TC, Young RC, McKoy WM, Grotzinger KR, Green JA, Chu EW, Whang-Peng J, Rogan AM, Green WR and Ozols RF (1983) Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res 43: 5379-5389
15. Houba PHJ, Leenders RGG, Boven E, Scheeren JW, Pinedo HM and Haisma HJ (1996a) Characterization of novel anthracycline prodrugs activated by human β-glucuronidase for use in antibody-directed enzyme prodrug therapy. Biochem Pharmacol 52: 455-463
16. Houba PHJ, Boven E, Haisma HJ (1996b) Improved characteristics of a human β-glucuronidase-antibody conjugate after deglycosylation for use in antibody-directed enzyme prodrug therapy. Bioconj Chem 7: 606-611
17. Kearney AS (1996) Prodrugs and targeted drug delivery. Adv Drug Del Rev 19: 225-239
18. Molthoff CFM, Calame JJ, Pinedo HH and Boven E (1991) Human ovarian cancer xenografts in nude mice: characterization and analysis of antigen expression. Int J Cancer 47: 72-79
19. Schumacher U, Adam E, Zangemeister-Wittke U and Gossrau R (1996) Histochemistry of therapeutically relevant enzymes in human tumours transplanted into severe combined immunodeficient (SCID) mice: nitric oxide synthase-associated diaphorase. β-D-glucuronidase and non-specific alkaline phosphatase. Acta Histochem 98: 381-387
20. Sinhababu AK and Thakker DR (1996) Prodrugs of anticancer agents. Adv Drug Del Rev 19: 241-273